Working to Eradicate Gynecologic Cancers

RANDOMIZED PHASE 2 EVALUATION OF BEVACIZUMAB VERSUS BEVACIZUMAB/FOSBRETABULIN IN RECURRENT OVARIAN, TUBAL OR PERITONEAL CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY

Sunday, March 29, 2015: 12:01 PM
International Ballroom (Hilton Chicago)
B. J. Monk
University of Arizona Cancer Center, Phoenix, AZ
 
 
See more of: Seminal Abstract Session
See more of: Seminal Session
<< Previous Presentation | Next Presentation >>